Skip to Main Content


Skip Nav Destination

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

Cancer Res (2022) 82 (4_Supplement): OT1-10-02.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Niraj Neupane
  • Sawyer Bawek
  • Sayuri Gurusinghe
  • Elham Moases Ghaffary
  • Omid Mirmosayyeb
  • Sangharsha Thapa
  • Carla Falkson
  • Ruth O’Regan
  • Ajay Dhakal
Cancers (2024) 16 (3): 619.
  • Teesha Downton
  • Fiona Zhou
  • Davendra Segara
  • Rinath Jeselsohn
  • Elgene Lim
Drug Design, Development and Therapy (2022) Volume 16: 2933.
Close Modal

or Create an Account

Close Modal
Close Modal